KMB
53
2
TRV
43
-2
KLAC
57
3
GPC
61
-3
MSFT
60
2
FIS
29
-4
CB
53
6
K
44
3
NFLX
58
-4
CHK
41
7
AEP
42
2
LNC
46
-2
SYF
81
7
XRAY
37
2
FFIV
63
2
EQT
60
4
HCP
62
8
HON
58
-4
DHR
50
-2
NSC
42
-8
KMB
53
2
TRV
43
-2
KLAC
57
3
GPC
61
-3
MSFT
60
2
FIS
29
-4
CB
53
6
K
44
3
NFLX
58
-4
CHK
41
7
AEP
42
2
LNC
46
-2
SYF
81
7
XRAY
37
2
FFIV
63
2
EQT
60
4
HCP
62
8
HON
58
-4
DHR
50
-2
NSC
42
-8
Financhill
Back

Haemonetics 10K Form

Buy
70

HAE
Haemonetics

Last Price:
87.65
Seasonality Move:
3.26%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-02 10Q HAE/Haemonetics Quarterly
2023-08-08 10Q HAE/Haemonetics Quarterly
2023-02-07 10Q HAE/Haemonetics Quarterly
2022-11-08 10Q HAE/Haemonetics Quarterly
2022-08-10 10Q HAE/Haemonetics Quarterly
2022-02-08 10Q HAE/Haemonetics Quarterly

Receive HAE News And Ratings

See the #1 stock for the next 7 days that we like better than HAE

HAE Financial Statistics

Sales & Book Value

Annual Sales: $1.17B
Cash Flow: $-22.83M
Price / Cash Flow: 34.39
Annual Sales: $18.57
Price / Book: 4.64

Profitability

EPS (TTM): 2.46000
Net Income (TTM): $126.57M
Gross Margin: $615.1M
Return on Equity: 14.73%
Return on Assets: 6.34%

Haemonetics Earnings Forecast

Key Haemonetics Financial Ratios

  • The Gross Profit Margin over the past 32 years for HAE is 52.63%.
  • The Selling, General & Administrative Expenses for HAE have been equal to 32.23% of Gross Profit Margin.
  • The Research & Development expenses have been 4.29% of Revenue.
  • The Interest Expense is 12.68% of Operating Income.
  • The Net Earning history of HAE is 9.87% of Total Revenues.
  • Per Share Earnings over the last 33 years have been positive in 20 years.

Haemonetics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: HAE
CUSIP: 405024
Website: haemonetics.com

Debt

Debt-to-Equity Ratio: 0.92
Current Ratio: 2.92
Quick Ratio: 1.55

Price-to-Earnings

Trailing P/E Ratio: 38.49
Forward P/E Ratio: 17.11

HAE Technical Analysis vs Fundamental Analysis

Buy
70
Haemonetics (HAE) is a Buy

Is Haemonetics a Buy or a Sell?

  • Haemonetics stock is rated a Buy
    The current Haemonetics [HAE] share price is $86.22. The Score for HAE is 70, which is 40% above its historic median score of 50, and infers lower risk than normal.